Regulatory Strategy and FDA Alignment Consulting

The contract seeks regulatory consulting services to ensure that preservation technologies for cell and tissue therapies are fully aligned with FDA regulatory frameworks, facilitating smoother pathway to compliance and market access. The work will focus on developing and advancing New Approach Methods designed to replace or reduce reliance on animal testing, aligning with modernized, human-relevant scientific standards. This effort supports broader goals within the Department of Health and Human Services to modernize evaluation methodologies and enhance the efficiency and safety of advanced therapeutic products. The contract is structured as a subcontract under the Advanced Research Projects Agency for Health and is classified under NAICS code 541611, indicating it involves management, scientific, and technical consulting services. Responses are due by May 12, 2026, and performance is expected to be centered in Washington. The initiative reflects a strategic push to integrate cutting-edge science with regulatory expectations, prioritizing innovation in testing approaches while maintaining rigorous safety and efficacy benchmarks for cell and tissue-based therapies.